title: Wilson's disease: A review of what we have learned.
abstract: Wilson's disease (WD), which results from the defective ATP7B protein product, is characterized by impaired copper metabolism and its clinical consequences vary from an asymptomatic state to fulminant hepatic failure, chronic liver disease with or without cirrhosis, neurological, and psychiatric manifestations. A high grade of suspicion is warranted to not miss cases of WD, especially less florid cases with only mild elevation of transaminases, or isolated neuropsychiatric involvement. Screening in first and second relatives of index cases is mandatory, and treatment must commence upon establishment of diagnosis. Treatment strategies include chelators such as D-penicillamine and trientine, while zinc salts act as inductors of methallothioneins, which favor a negative copper balance and a reduction of free plasmatic copper. As an orphan disease, research is lacking in this field, especially regarding therapeutic strategies which are associated with better patient compliance and which could eventually also reverse established injury.
authors.affiliation: Kryssia Isabel Rodriguez-Castro, Gastroenterology and Endoscopy, Policlinico Abano Terme, 35031 Abano Terme, Padua, Italy.
authors.forename: Kryssia Isabel
authors.initials: KI
authors.lastname: Rodriguez-Castro
authors.affiliation: Kryssia Isabel Rodriguez-Castro, Gastroenterology and Endoscopy, Policlinico Abano Terme, 35031 Abano Terme, Padua, Italy.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Hevia-Urrutia
authors.affiliation: Kryssia Isabel Rodriguez-Castro, Gastroenterology and Endoscopy, Policlinico Abano Terme, 35031 Abano Terme, Padua, Italy.
authors.forename: Giacomo Carlo
authors.initials: GC
authors.lastname: Sturniolo
keywords: Chelating agents; Copper; Liver transplantation; Orphan disease; Penicillamine; Wilson disease; Wilson’s disease; Zinc